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Bone Mineral Density and Risk of Heart Failure in Older Adults: The
Cardiovascular Health Study
Raymond B. Fohtung, MD; David L. Brown, MD; William J. H. Koh, MS; Traci M. Bartz, MS; Laura D. Carbone, MD, MS; Roberto Civitelli, MD;
Phyllis K. Stein, PhD; Paulo H. M. Chaves, MD, PhD; Bryan R. Kestenbaum, MD, MS; Jorge R. Kizer, MD, MSc
Background-—Despite increasing evidence of a common link between bone and heart health, the relationship between bone
mineral density (BMD) and heart failure (HF) risk remains insufﬁciently studied.
Methods and Results-—We investigated whether BMD measured by dual-energy x-ray absorptiometry was associated with incident
HF in an older cohort. Cox models were stratiﬁed by sex and interactions of BMD with race assessed. BMD was examined at the
total hip and femoral neck separately, both continuously and by World Health Organization categories. Of 1250 participants, 442
(55% women) developed HF during the median follow-up of 10.5 years. In both black and nonblack women, neither total hip nor
femoral neck BMD was signiﬁcantly associated with HF; there was no signiﬁcant interaction by race. In black and nonblack men,
total hip, but not femoral neck, BMD was signiﬁcantly associated with HF, with evidence of an interaction by race. In nonblack men,
lower total hip BMD was associated with higher HF risk (hazard ratio, 1.13 [95% CI, 1.01–1.26] per 0.1 g/cm2 decrement),
whereas in black men, lower total hip BMD was associated with lower HF risk (hazard ratio, 0.74 [95% CI, 0.59–0.94]). There were
no black men with total hip osteoporosis. Among nonblack men, total hip osteoporosis was associated with higher HF risk (hazard
ratio, 2.83 [95% CI, 1.39–5.74]) compared with normal BMD.
Conclusions-—Among older adults, lower total hip BMD was associated with higher HF risk in nonblack men but lower risk in black
men, with no evidence of an association in women. Further research is needed to replicate these ﬁndings and to study potential
underlying pathways. ( J Am Heart Assoc. 2017;6:e004344. DOI: 10.1161/JAHA.116.004344.)
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H eart failure (HF) and osteoporosis are highly prevalentaging-related diseases that exact an enormous toll on
society. In the United States, where some 5.7 million adults
are affected, HF ranks as the leading cause of hospitalization,
and carries a mortality rate of 50% within 5 years of
diagnosis.1 With the aging of the US population, the burden of
HF is expected to signiﬁcantly increase in the coming
decades.2 In the United States, osteoporosis and low bone
mineral density (BMD) affect an estimated 53 million people,
predominantly women and individuals of European descent.3
As a result, an estimated 1 in 2 women, and 1 in 5 men, will
experience an osteoporotic fracture during their lifetime.3
Osteoporotic fractures, in particular, hip fractures, are asso-
ciated with substantial costs and morbidity and carry a 1-year
mortality rate of about 20%.4
Although HF and osteoporosis are generally thought of as
separate diseases, the two have been linked. Epidemiological
studies have found that having HF predisposes patients to low
BMD and hip fracture, an association that is partly attributable
to reduced physical activity and the effects of vasoactive and
diuretic medications.5–7 However, common mechanisms
involving various biochemical pathways8–13 may also be
important in this link and could possibly drive this association
in the opposite direction, with low BMD predisposing to HF.
Such mechanisms may involve coronary atherosclerosis,14
which has been associated with low BMD,15,16 or affect the
myocardium directly. A population-based European study
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examined this question using broadband ultrasound attenu-
ation to measure BMD at the calcaneus and documented an
inverse association of broadband ultrasound attenuation with
incident HF risk, especially HF without antecedent myocardial
infarction.17
No study to date has assessed low BMD as a risk factor for
HF using dual-energy x-ray absorptiometry (DXA), which is the
recommended method for determining BMD in clinical
practice.3 Nor has the impact of race on the relationship
between BMD and HF been examined, particularly in blacks,
who are at higher risk for incident HF compared with whites.18
In addition, there are substantial differences in bone strength,
density, and microarchitecture between blacks and whites,
partly attributed to a signiﬁcantly greater cortical thickness
and trabecular volumetric BMD in blacks.19 As a result, blacks
have a lower fracture risk and prevalence of osteoporosis
compared with whites.3 To address these gaps, we investi-
gated whether total hip and femoral neck BMD was associ-
ated with incident HF among older adults participating in the




CHS is a population-based longitudinal study of risk factors
associated with development of cardiovascular disease (CVD)
in older adults (≥65 years).20 Medicare-eligible individuals
were recruited from four US communities, including Sacra-
mento County, CA; Washington Country, MD; Forsyth County,
NC; and Allegheny County, PA. Eligible individuals had to be
noninstitutionalized, expect to remain in the area for the
following 3 years, receive no active cancer treatment, not be
wheelchair-bound at home, and be capable of providing
consent without requiring a proxy at entry. Household
members of those sampled were recruited if eligible. The
institutional review boards at all clinical centers and the
coordinating center approved the study and all participants
provided informed consent. Initially, 5201 mostly white
participants were recruited in 1989–1990 (original cohort),
followed by 687 predominantly black participants in 1992–
1993 (supplemental cohort).
Of the 5888 participants recruited to CHS, 4842 partic-
ipated in the 1994–1995 examination, which is the baseline
for this study. In this examination, DXA scans were performed
on participants in 2 of the 4 sites (Sacramento and Allegheny
Counties) for determination of BMD. Scans were offered to
participants in the order in which they came to the ﬁeld
centers for their visit until funding for these scans was
exhausted. In total, 1576 participants (32.5%) underwent DXA
scanning. Of these, we excluded 95 for prevalent HF, 37 for
current use of corticosteroids, and 9 for both prevalent HF
and use of corticosteroids. An additional 185 participants
were excluded because of missing covariates for multivariable
analysis. Our analytic sample thus included 1250 participants.
Measurement of BMD
DXA scans were performed with QDR 2000 densitometers
(Hologic, Inc, Bedford, MA), using the array beam mode.
Scans were read blindly at the University of California San
Francisco Reading Center using Hologic software version
7.10, as previously described.21 The primary measures of
interest were BMD of the total hip and BMD of the femoral
neck.
Ascertainment and Adjudication of Incident HF
Outcome
Follow-up consisted of annual in-person examinations alter-
nating with semiannual telephone interviews between 1989
and 1999. Thereafter, telephone interviews continued semi-
annually, with one additional in-person examination in 2005–
2006. Ascertainment and adjudication of incident HF events
have been previously described.22 Brieﬂy, an expert panel
reviewed all relevant data from hospitalizations or outpatient
visits, including history, physical examination, report of chest
radiography, and medication usage. Any self-report of a
physician diagnosis of HF obtained during in-person visits and
telephone contacts was conﬁrmed by reviewing the medical
record for documentation of a series of symptoms and
physical signs (such as shortness of breath, fatigue, orthop-
nea, paroxysmal nocturnal dyspnea, edema, pulmonary rales,
gallop rhythm, or displaced left ventricular apical impulse) or
supporting clinical ﬁndings, such as those on chest radiog-
raphy. For participants with a previous physician diagnosis of
HF, the diagnosis was conﬁrmed if the participant was
receiving medical therapy for HF such as a current prescrip-
tion for a diuretic and digitalis or a vasodilator (nitroglycerin,
hydralazine, or angiotensin-converting enzyme inhibitor). The
present report includes HF events adjudicated from baseline
(year of BMD measurement) through June 30, 2013, for a
maximum follow-up of 19 years.
Assessment and Deﬁnition of Baseline Covariates
Participants received standardized health assessments involv-
ing questionnaires, anthropometry, physical examination,
blood collection, electrocardiography, and spirometry during
their study visits, as previously described.20 Physical activity
was determined using a validated questionnaire.23 The Core
Laboratory at the University of Vermont performed measure-
ments on blood samples, as detailed elsewhere.24–26
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Most variables including body weight, systolic blood
pressure, smoking, systemic estrogen use, and treatment
with antihypertensive medication were collected or mea-
sured in 1994–1995. For variables that were not assessed in
1994–1995, we used information from the closest prior
examination where data were available, under the assumption
that earlier values would be a reasonable proxy for current
values. Physical activity, cystatin C, C-reactive protein
(CRP), and height and waist circumference were measured
in 1992–1993 and forced expiratory volume in 1 second was
measured in 1993–1994. Body mass index was calculated
using height measured in 1992–1993 and weight measured
in 1994–1995. When not available at the 1992–1993
examination, height was carried forward from the CHS
baseline examination in 1989–1990. Smoking was assessed
in 1994–1995 and when missing was carried forward from
the 1992–1993 visit.
Diabetes mellitus was deﬁned as fasting glucose
≥126 mg/dL, nonfasting glucose ≥200 mg/dL, or treatment
with oral hypoglycemic medications or insulin, based on the
1994–1995 visit or closest prior visit if missing. Cystatin C
was used to calculate estimated glomerular ﬁltration rate
(eGFR) using standard methods.27,28
Prevalent CVD including coronary heart disease (CHD),
stroke or transient ischemic attack, peripheral arterial disease,
and HF were ascertained at the initiation of CHS and incident
events adjudicated during follow-up from self-reported infor-
mation obtained at semiannual contacts.29,30 Atrial ﬁbrillation
was ascertained through a combination of annual ECGs and
hospital or outpatient diagnostic codes.31 Prevalent CVD and
atrial ﬁbrillation at baseline for the current study were
determined through such ascertainment, and include events
from the start of CHS to the 1994–1995 examination, while
incident CHD was based on surveillance thereafter, comprising
events after the 1994–1995 examination.
Statistical Analysis
All analyses were stratiﬁed a priori by sex. Baseline charac-
teristics were summarized using means (SDs) or medians
(interquartile ranges) for continuous variables and counts
(percentages) for categorical variables. Comparisons of
baseline characteristics between blacks and nonblacks in
each sex group were performed with t tests (allowing for
unequal variances) and chi-square tests for continuous and
categorical variables, respectively. Cross-sectional associa-
tions of BMD with covariates were examined using Pearson
correlation coefﬁcients for continuous variables, and linear
regression for comparison of means across levels of cate-
gorical variables.
Total hip and neck BMD were evaluated both as continuous
and categorical variables. Categories of BMD were based on
the World Health Organization classiﬁcation of osteoporosis
using T-scores. T-scores were obtained by calculating the
number of SDs that the raw BMD values were from the
average BMD in a population-based sample of non-Hispanic
white women aged 20 to 29 years.32 T-scores were catego-
rized as normal BMD (T-score ≥1.0), osteopenia (1.0> T-
Score >2.5) or osteoporosis (T-score ≤2.5). Of note,
herein we refer to osteoporosis (or osteopenia) of the femoral
neck or total hip to designate low BMD at those sites,
recognizing that osteoporosis-level (osteopenia-level) BMD at
either site is sufﬁcient for a diagnosis of osteoporosis
(osteopenia) for the affected individual.
In our primary analyses, we examined the association of
BMD at baseline (1994–1995) with incidence of HF during
follow-up. We report hazards ratios (HRs), Wald-based 95%
CIs, and Wald-based P values based on Cox proportional
hazards regression performed in men and women separately.
Because we had a priori reasons to believe that the
association of BMD with HF might differ between blacks
and nonblacks (white [99.6%], American Indian, Alaskan
native, Asian, Paciﬁc Islander, and other), all analyses included
a test for interaction by race using the Wald test, and the
results were reported by race in both men and women
regardless of signiﬁcance. For analyses of the association of
continuous BMD with incident HF, we assessed the functional
forms of the associations using penalized cubic splines after
including potential confounders from the fully adjusted model,
as described below.
We ﬁt models adjusting sequentially for covariates
selected based on previously documented associations with
HF. In our ﬁrst model, the association of BMD with incident HF
was adjusted for age at BMD measurement. In our second
model, we additionally adjusted for body mass index, systolic
blood pressure, antihypertensive medications, prevalent dia-
betes mellitus, smoking (none, current, or former smoker),
alcohol consumption, estrogen replacement (in women), and
physical activity (logarithm of kcal per week+1). In our ﬁnal
and fully adjusted model, we additionally adjusted for forced
expiratory volume in 1 second, eGFR, and CRP and prevalent
CHD, stroke/transient ischemic attack, peripheral arterial
disease and atrial ﬁbrillation. Last, in secondary analyses, we
additionally adjusted for aspirin and/or digitalis use or waist
circumference to assess their impact on the associations of
interest.
Sensitivity analyses were conducted to exclude partici-
pants with possible subclinical HF at baseline. These sensi-
tivity analyses examined the inﬂuence of excluding
participants with N-terminal pro B-type natriuretic peptide
(NT-proBNP) ≥190 pg/mL26 or starting follow-up for incident
HF 2 years after DXA scan. Sensitivity analyses were
performed for continuous BMD only. In addition, we investi-
gated the inﬂuence of time-dependent CHD on the association
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of BMD with incident HF in our fully adjusted model for both
continuous and categorical BMD. Statistical analyses were
conducted using STATA version 14 (StataCorp, College
Station, TX), excepting the functional form of the ﬁnal Cox
model, which was assessed in R3.1.1. A two-tailed P<0.05
was considered statistically signiﬁcant.
W.J.H.K. had full access to all data in the study and takes
responsibility for its integrity and the data analysis.
Results
Baseline Characteristics
Baseline characteristics of the cohort, stratiﬁed by sex, are
summarized in Table 1. The study cohort comprised 1250
participants with a mean age of 765 years. Of these, 59%
were women and 19% were black. Black women and men
were younger; had higher prevalence of hypertension and
diabetes mellitus; consumed less alcohol but engaged in less
frequent exercise; had less prevalent use of lipid-lowering,
estrogen (women), aspirin, and digitalis therapy; and had
higher CRP and eGFR levels but lower triglycerides and forced
expiratory volume in 1 second, as compared with their
nonblack counterparts. Black women had higher waist
circumference and low-density lipoprotein but lower high-
density lipoprotein than white women, whereas the opposite
was true in men. Black men had lower prevalent CHD than
nonblack men, but black women had more prevalent stroke/
transient ischemic attack than black women. BMD was lower
in nonblacks than blacks for both sexes at both the total hip
and femoral locations.
Association of Baseline Covariates With BMD
Descriptive results for the association of baseline covariates
with continuous total hip BMD in women and men are
summarized in Table 2. In both sexes, total hip BMD was
negatively correlated with age but positively associated with
measures of adiposity, prevalent diabetes mellitus, and
triglycerides. In women, antihypertensive medication and
current estrogen use, along with higher forced expiratory
volume in 1 second and CRP levels, were associated with
higher total hip BMD, whereas prevalent atrial ﬁbrillation was
associated with lower total hip BMD. In men, total hip BMD
was positively correlated with physical activity, alcohol
consumption, and eGFR. Results for femoral neck BMD were
similar (Table S1).
Incident HF Events
Over a median follow-up of 10.5 years, there were 442
incident HF events. Of these, 245 (55%) occurred in women,
including 48 (11%) in black women and 197 (45%) in nonblack
women. In addition, 197 (45%) incident HF events occurred in
men, including 33 (7%) in black men and 164 (37%) in
nonblack men. The number and incidence rates of HF events
across BMD categories are summarized in Table 3. The
highest event rates occurred for nonblack men with osteo-
porosis of the femoral neck and, especially, total hip. The
marked differences in HF incidence by BMD category noted
for nonblack men were not observed in women of either race.
The incidence rate of HF for black men with osteopenia at the
femoral neck was comparable to normal BMD, but lower at
the total hip, although the subset with osteopenia at the total
hip was especially small. There were no black men and few
black women with total hip osteoporosis, and the numbers of
black men and women with osteoporosis of the femoral neck
were similarly scant. As a consequence, Cox regression
analyses of the categories of total hip and femoral neck BMD
were restricted to nonblacks.
Results of the Primary Analyses
Results of the primary analyses are summarized in Table 4
and Figures 1 and 2. These ﬁndings are stratiﬁed by sex
and reported separately for blacks and nonblacks. Assess-
ment of the functional forms using penalized cubic
smoothing splines showed that the associations of contin-
uous total hip and femoral neck BMD with HF were
consistent with linear trends. In summary, in women, there
was no signiﬁcant association of BMD with incident HF and
no evidence of interaction of BMD with race. In men, there
was a signiﬁcant association of BMD with incident HF at
the total hip only and signiﬁcant interaction of BMD with
race at the total hip and femoral neck. In men, this
association of BMD with incident HF was positive in blacks
and negative in nonblacks. The results of the primary
analyses are presented in detail below.
Lack of Association of Continuous or Categorical
BMD With Incident HF in Both Black and
Nonblack Women
Findings for the association of continuous total hip and
femoral neck BMD with incident HF are summarized in
Table 4. In both black and nonblack women, there was no
signiﬁcant association of continuous BMD with incident HF
in the fully adjusted model (total hip: HR, 0.97 [95% CI,
0.85–1.10] for nonblacks; HR, 1.11 [95% CI, 0.89–1.39] for
blacks). There was also no signiﬁcant effect modiﬁcation of
continuous BMD by race (total hip BMD, P=0.273; femoral
neck BMD, P=0.466).
Results for the association of categories of total hip and
femoral BMD with incident HF in nonblacks are summarized in
DOI: 10.1161/JAHA.116.004344 Journal of the American Heart Association 4






















Table 1. Baseline Characteristics of the Study Cohort Stratiﬁed by Sex and Race
Characteristics
Women Men
Black (n=145) Nonblack (n=589) P Value Black (n=91) Nonblack (n=425) P Value
Age, y 74.24.9 76.34.2 <0.001 74.84.6 77.14.7 <0.001
Body mass index, kg/m2 29.34.6 26.34.8 <0.001 26.73.8 26.63.6 <0.001
Waist circumference, cm 101.214.2 93.614.3 <0.001 95.910.9 98.49.3 <0.001
Systolic blood pressure, mm Hg 13619 13421 <0.001 13422 13119 <0.001
Antihypertensive medication,* No. (%) 104 (72) 263 (45) <0.001 48 (53) 216 (51) 0.739
Diabetes mellitus, No. (%) 37 (26) 51 (9) <0.001 24 (26) 66 (16) 0.013
Smoking, No. (%) 0.328 <0.001
Never smoker 65 (45) 302 (51) 22 (24) 114 (27)
Former smoker 67 (46) 233 (40) 52 (57) 287 (68)
Current smoker 13 (9) 54 (9) 17 (19) 24 (6)
Alcohol, drinks per wk 0 (0–0) 0 (0–1) <0.001 0 (0–3) 1 (0–7) <0.001
Physical activity, kcal per wk 490 (180–1255) 930 (322.5–2017.5) <0.001 867 (315–1843) 1413 (540–3175) <0.001
Low-density lipoprotein, mg/dL 13438 13232 <0.001 12031 12229 <0.001
High-density lipoprotein, mg/dL 5814 5915 <0.001 5211 4611 <0.001
Triglycerides, mg/dL 103 (79–142) 124 (90–170) <0.001 91 (73–130) 112 (83–158) <0.001
Lipid-lowering medication, No. (%) 14 (10) 69 (12) <0.001 5 (5) 35 (8) <0.001
Aspirin, No. (%) 40 (28) 237 (40) <0.001 29 (32) 183 (43) <0.001
Digitalis, No. (%) 8 (6) 35 (6) <0.001 7 (8) 40 (9) <0.001
Estrogen use, No. (%) 15 (10) 122 (21) 0.004  
Prevalent coronary heart disease, No. (%) 29 (20) 82 (14) 0.067 17 (19) 128 (30) 0.028
Prevalent stroke/transient ischemic
attack, No. (%)
10 (7) 17 (3) 0.022 10 (11) 37 (9) 0.492
Prevalent peripheral arterial disease, No. (%) 3 (2) 7 (1) 0.413 5 (5) 24 (6) 0.954
Prevalent atrial fibrillation, No. (%) 8 (6) 30 (5) 0.837 3 (3) 35 (8) 0.102
Serum creatinine, mg/dL 0.90.3 0.90.2 <0.001 1.20.3 1.20.2 <0.001
Estimated glomerular filtration rate
(cystatin-based), mL/min per 1.73 m2
8523 7718 <0.001 8217 7115 <0.001
Forced expiratory volume in 1 s, L 1.60.4 1.80.4 <0.001 2.10.6 2.50.6 <0.001
C-reactive protein, mg/L 4.9 (2.0–9.3) 2.4 (1.1–5.6) <0.001 2.2 (1.0–4.2) 1.9 (1.0–4.0) <0.001
Total hip BMD, g/cm2 0.90.1 0.70.1 <0.001 1.00.2 0.90.2 <0.001
Femoral neck BMD, g/cm2 0.80.1 0.60.1 <0.001 0.90.2 0.80.1 <0.001
Total hip, WHO categories, No. (%) <0.001 0.004
Normal 73 (50) 83 (14) 75 (82) 283 (67)
Osteopenia 53 (37) 282 (48) 16 (18) 120 (28)
Osteoporosis 19 (13) 224 (38) 0 (0) 22 (5)
Femoral neck, WHO categories, No. (%) <0.001 <0.001
Normal 58 (40) 53 (9) 64 (70) 181 (43)
Osteopenia 69 (48) 271 (46) 24 (26) 205 (48)
Osteoporosis 18 (12) 265 (45) 3 (3) 39 (9)
Data for continuous variables are presented as meanSD or median (interquartile range). BMD indicates bone mineral density; WHO, World Health Organization.
*Antihypertensive medication deﬁned as the use of b-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, vasodilators, or diuretics.
DOI: 10.1161/JAHA.116.004344 Journal of the American Heart Association 5






















Table 2. Cross-Sectional Association of Continuous Total Hip BMD With Baseline Characteristics of the Study Cohort
Characteristics
Total Hip BMD
Women (n=734) Men (n=516)
No.
Correlation
Coefﬁcient MeanSD P Value No.
Correlation
Coefﬁcient MeanSD P Value
Age, y 734 0.32 <0.001 516 0.21 <0.001
Body mass index, kg/m2 734 0.51 <0.001 516 0.36 <0.001
Waist circumference, cm 731 0.41 <0.001 516 0.22 <0.001
Systolic blood pressure, mm Hg 734 0.03 0.505 516 0.03 0.510
Antihypertensive medication
No 367 0.740.14 0.003 252 0.950.16 0.784
Yes 367 0.770.15 264 0.950.17
Diabetes mellitus
No 646 0.740.14 <0.001 426 0.940.16 0.011
Yes 88 0.840.16 90 0.990.17
Smoking status
Never smoker 367 0.750.14 0.345 136 0.940.17 0.677
Former smoker 300 0.760.15 339 0.950.16
Current smoker 67 0.730.13 41 0.940.16
Alcohol, drinks per wk 734 0.001 0.981 516 0.01 0.026
Physical activity, kcal per wk* 734 0.003 0.935 516 0.10 0.022
Low-density lipoprotein, mg/dL 726 0.001 0.981 509 0.03 0.556
High-density lipoprotein, mg/dL 733 0.05 0.148 516 0.01 0.899
Triglycerides, mg/dL 734 0.12 0.004 516 0.09 0.044
Lipid-lowering medication
No 651 0.750.14 0.313 476 0.950.16 0.333
Yes 83 0.770.15 40 0.920.19
Aspirin
No 454 0.750.14 0.483 302 0.950.16 0.732
Yes 277 0.750.14 212 0.950.17
Digitalis
No 691 0.750.14 0.972 469 0.950.16 0.586
Yes 43 0.750.15 47 0.960.20
Estrogen use
No 597 0.750.14 0.034
Yes 137 0.770.14
Prevalent coronary heart disease
No 623 0.750.14 0.776 371 0.950.16 0.449
Yes 111 0.750.16 145 0.940.18
Prevalent stroke/transient ischemic attack
No 707 0.750.14 0.926 469 0.950.16 0.204
Yes 27 0.750.15 47 0.920.18
Prevalent peripheral arterial disease
No 109 0.740.15 0.955 95 0.910.19 0.167
Continued
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Figures 1 and 2, respectively. Compared with normal BMD,
there was no evidence of signiﬁcant association of osteo-
porosis (or osteopenia) at the total hip (HR, 0.83; 95% CI,
0.54–1.28) or femoral neck (HR, 1.03; 95% CI, 0.64–1.64)
with incident HF in the fully adjusted model among nonblack
women.
Signiﬁcant Associations of Continuous and
Categorical BMD With Incident HF in Men
Results for the association of continuous total hip and femoral
neck BMD with incident HF in men are also summarized in
Table 4. There was a signiﬁcant interaction of BMD and race
in men (total hip BMD, P=0.001; femoral neck BMD,
P=0.009). In nonblack men, lower total hip BMD was
associated with a signiﬁcantly higher HF risk in the fully
adjusted model (HR, 1.13 [95% CI, 1.01–1.26] for every
0.1 g/cm2 decrement in BMD). In contrast, among black
men, lower total hip BMD was associated with a signiﬁcantly
lower risk of HF in the fully adjusted model (HR, 0.74 [95% CI,
0.59–0.94] for every 0.1 g/cm2 decrement in BMD). The
race-speciﬁc associations of femoral neck BMD with incident
HF were in the same direction as for total hip BMD but were
not statistically signiﬁcant (nonblack men: HR, 1.14 [95% CI,
0.99–1.30]; black men: HR, 0.79 [95% CI, 0.62–1.01]).
Findings for the association of categories of total hip and
femoral neck BMD with incident HF in nonblack men are also
summarized in Figures 1 and 2, respectively. Nonblack men
with osteoporosis at the total hip had a nearly 3-fold higher
risk of HF (HR, 2.83; 95% CI, 1.39–5.74 [P=0.004]) and
nonblack men with osteoporosis of the femoral neck had an
almost 2-fold risk of HF (HR, 1.88; 95% CI, 1.02–3.47
[P=0.043]) as compared with normal BMD at these sites.
Higher risk of HF was observed for osteopenia of the total hip
(HR, 1.35; 95% CI, 0.94–1.93 [P=0.104]) and of the femoral
neck (HR, 1.37; 95% CI, 0.96–1.95 [P=0.081]) relative to
normal BMD but these were not signiﬁcant (Figure 2).
Secondary and Sensitivity Analyses
The results in men and women for continuous and categorical
total hip and femoral neck BMD were similar after additionally
adjusting for aspirin, digitalis use, or waist circumference.
In sensitivity analyses excluding participants with




Women (n=734) Men (n=516)
No.
Correlation
Coefﬁcient MeanSD P Value No.
Correlation
Coefﬁcient MeanSD P Value
Yes 625 0.750.14 421 0.960.16
Prevalent atrial fibrillation
No 696 0.750.14 0.011 478 0.950.16 0.814
Yes 38 0.690.15 38 0.950.19
Creatinine, mg/dL 725 0.07 0.062 512 0.01 0.918
Estimated glumerular filtration rate (cystatin-based), mL/
min per 1.73 m2
734 0.06 0.085 516 0.09 0.033
Forced expiratory volume in 1 s, L 734 0.11 0.003 516 0.07 0.110
C-reactive protein, mg/L 734 0.11 0.004 516 0.02 0.723
BMD indicates bone mineral density.
*The logarithm of physical activity+1 was used to compute the correlation.
Table 3. HF Events During Follow-Up in Participants With
Normal BMD, Osteopenia, and Osteoporosis Stratiﬁed by Sex
and Race
Women Men
Black Nonblack Black Nonblack
Median follow-up, y 12.0 12.1 8.9 8.7
HF events
Total hip, No. (incidence rate*)
Normal BMD 25 (30.2) 36 (34.9) 29 (41.5) 103 (37.7)
Osteopenia 16 (23.9) 99 (28.8) 4 (23.6) 51 (48.7)
Osteoporosis 7 (39.9) 62 (26.3)  10 (96.6)
Femoral neck, No. (incidence rate*)
Normal BMD 19 (28.1) 22 (34.4) 25 (38.7) 58 (35.4)
Osteopenia 24 (29.1) 97 (29.1) 8 (41.3) 91 (46.5)
Osteoporosis 5 (28.9) 78 (27.3) 0 (0) 15 (53.3)
BMD indicates bone mineral density; HF, heart failure.
*Per 1000 person-years.
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DXA scan, ﬁndings were similar in women. After exclusion of
individuals with NT-proBNP ≥190 pg/mL in nonblack men,
lower total hip BMD remained signiﬁcantly associated with
higher HF risk (HR, 1.20; 95% CI, 1.03–1.40 [P=0.020]), and
lower femoral neck BMD was stronger and signiﬁcantly
associated with higher HF risk (HR, 1.22 per 0.1 g/cm2; 95%
CI, 1.02–1.46 [P=0.030]). In black men, the association of
total hip BMD with incident HF became weaker and no longer
statistically signiﬁcant (HR, 0.81; 95% CI, 0.61–1.07
[P=0.142]), although evidence of an interaction of BMD with
race remained (P=0.013). The association between femoral
neck BMD with HF in black men was similar in the fully
adjusted model (HR, 0.81; 95% CI, 0.61–1.08 [P=0.147]).
The sensitivity analysis starting follow-up 2 years after
DXA scan showed similar ﬁndings. In nonblack men, lower
total hip BMD remained signiﬁcantly associated with
higher HF risk (HR, 1.14; 95% CI, 1.01–1.28 [P=0.032]) and
lower femoral neck BMD again was signiﬁcantly associated
with higher HF risk (HR, 1.17; 95% CI, 1.02–1.34 [P=0.030]).
In black men, the association of total hip BMD with HF was
attenuated (HR, 0.82; 95% CI, 0.63–1.07 [P=0.149]). For
femoral neck BMD, the results were similar (HR, 0.82; 95% CI,
0.62–1.07 [P=0.144]).
Additional adjustment for CHD as a time-dependent
covariate had similar results for continuous BMD of both
total hip and femoral neck (both black and nonblack men),
and categorical BMD at the total hip among nonblack men.
Among nonblack men, the risk estimate for osteoporosis of
the femoral neck was similar (HR, 1.85; 95% CI, 1.001–3.41
[P=0.0497]), while osteopenia of the femoral neck with HF




In this population-based study of older adults, we did not ﬁnd
a signiﬁcant association between total hip or femoral neck
BMD and incident HF in women. Among men, however, there
was evidence of a signiﬁcant association and also effect
modiﬁcation by race. Lower total hip BMD was independently
associated with higher HF risk in nonblack men, but lower risk
in black men. Findings were similar for femoral neck BMD,
although these fell short of statistical signiﬁcance, possibly
reﬂecting DXA’s higher precision errors for BMD at the
femoral neck than the total hip.33 The statistically signiﬁcantly
higher risk of HF with lower BMD of the hip in nonblack men
persisted after exclusion of subclinical HF (NT-proBNP
≥190 pg/mL), although the lower risk of HF with lower
BMD in black men was attenuated and no longer signiﬁcant.
Prior Studies
To our knowledge, only one previous study has examined the
association of BMD with incident HF risk. This study assessed
Table 4. Association Between BMD of the Total Hip or Femoral Neck and Incident Heart Failure Stratiﬁed by Sex
Group
Women (n=734) Men (n=516)



















































*Per 0.1 g/cm2 decrement in bone mineral density (BMD).
†Adjusted for age, body mass index, systolic blood pressure, antihypertensive medication, diabetes mellitus, smoking, alcohol consumption, physical activity, estrogen replacement
(women), prevalent coronary heart disease, prevalent stroke or transient ischemic attack, prevalent peripheral arterial disease, prevalent atrial ﬁbrillation, estimated glomerular ﬁltration
rate, forced expiratory volume in 1 second, and C-reactive protein.
‡Ratio of hazard ratio (HR) between black and nonblack groups.
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a cohort of 13 666 British adults, aged 42 to 82 years, who
participated in the EPIC-Norfolk (European Prospective Inves-
tigation into Cancer and Nutrition-Norfolk) study.17 Partici-
pants were followed for a mean of 9.3 years, similar to the
median follow-up of 10.5 years in our study.17 The EPIC-
Norfolk study found that lower BMD at the calcaneus was
associated with higher HF risk. The study found no evidence
of effect modiﬁcation by sex, and risk estimates were similar
in men and women although the association was not
signiﬁcant in women. The EPIC-Norfolk study did not report
testing of effect modiﬁcation by race.
Among other notable differences between the EPIC-
Norfolk study and the present investigation, participants in
the British study were younger (mean age 629 versus
765 years), which likely accounts for the lower incidence
of HF events (2.8%) compared with that reported here
(35.4%). Also, while the EPIC-Norfolk investigation used
broadband ultrasound attenuation of the calcaneus to
measure BMD, our study used DXA scans of the total hip
and femoral neck. In addition, the British study based
incident HF events on inpatient International Classiﬁcation of
Disease, 9th and 10th revision codes only, whereas our
study used adjudicated incident HF events. Last, like the
EPIC-Norfolk report, we accounted for a series of potential
confounders in our analyses. We additionally included
measures of chronic kidney disease (cystatin C-based eGFR)
0 1 2 3 4 5 6
Adjusted Hazard Ratio for Incident Heart Failure
Osteopenia vs Normal 
BMD, women
Osteoporsis vs Normal 
BMD, women
Osteopenia  vs Normal 
BMD, men
Osteoporosis vs Normal 
BMD, men
Figure 1. Adjusted hazard ratio for incident heart failure by World Health Organization classiﬁcation of
osteoporosis or osteopenia compared with normal bone mineral density (BMD) at the total hip in nonblacks.
Models are fully adjusted.
0 1 2 3 4 5 6
Adjusted Hazard Ratio for Incident Heart Failure








Figure 2. Adjusted hazard ratio for incident heart failure by World Health Organization classiﬁcation of
osteoporosis or osteopenia compared with normal bone mineral density (BMD) at the femoral neck in
nonblacks. Models are fully adjusted.
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and inﬂammation (CRP), however, which allowed for more
extensive assessment for potential confounding.
Potential Explanation of Findings in Nonblack
Men
The association between low BMD and increased risk of HF
documented here among nonblack men has several potential
explanations, some of which have been previously dis-
cussed.17 One possibility is that the association may be
driven by shared risk factors of osteoporosis and HF, including
advancing age, sedentary lifestyle, and kidney disease. In our
analyses, however, the observed association persisted after
adjustment for these factors, making this potential explana-
tion unlikely.
Given evidence that HF is a risk factor for osteoporosis and
fractures,5–7,34 another potential explanation is that the
inverse association in nonblack men could reﬂect subclinical
HF at the time of BMD measurement. To address this
possibility, we performed sensitivity analyses excluding par-
ticipants with NT-proBNP ≥190 pg/mL at the time of DXA
scan, and moving the start of the HF follow-up to 2 years after
DXA scans. Neither analysis showed a noticeable change in
the inverse association of BMD with incident HF in nonblack
men, arguing against reverse causation.
Hence, the inverse association documented here among
nonblack men is consistent with the premise that aging-
related processes leading to osteoporosis in this group may
relate, and possibly contribute, to mechanisms involved in the
pathogenesis of HF. In this regard, various experimental and
clinical studies have identiﬁed molecular pathways that
provide a link between low BMD and increased HF risk.
Some of these pathways involve the parathyroid hormone–
vitamin D axis. Notably, elevated parathyroid hormone and
low vitamin D levels, which can be associated with bone
catabolism, have been shown to predict HF hospitalization
and death, respectively.8,9 Also, vitamin D has been docu-
mented to be a negative endocrine regulator of the renin-
angiotensin system, which is an important system in the
pathophysiology of HF.9 Other pathways involve receptor
activator of nuclear factor j-B ligand, a protein known to
stimulate bone resorption. For example, neurohormonal
activation and higher levels of adrenergic agonists in HF have
been shown to stimulate or increase levels of receptor
activator of nuclear factor j-B ligand.11,12 Receptor activator
of nuclear factor j-B ligand has also been shown to
upregulate metalloproteinase activity in ﬁbroblasts that could
potentially contribute to adverse left ventricular remodeling.13
Although these mechanisms are plausible, further research is
needed to elucidate their role.
In addition to these direct myocardial pathways, low BMD
is associated with vascular calciﬁcation through a number of
mechanisms.14 Although the relationship between osteoporo-
sis and atherosclerotic CVD has been documented,15,16 we
found the association to persist despite adjustment for CHD
at baseline and during follow-up, suggesting that the expla-
nation goes beyond ischemic heart disease. Apart from
coronary atherosclerosis, calciﬁcation of the aorta is another
potentially important mechanism, which, by fostering arterial
stiffness and central blood pressure augmentation, could
promote cardiac hypertrophy and lead to the development of
HF.35,36 Measures of vascular stiffness were not available in
CHS, and their impact could not be evaluated here, although it
bears noting that adjusting for systolic blood pressure as a
surrogate of aortic stiffness did not materially inﬂuence the
association in question.
Potential Explanation of Findings in Black Men
The association of lower BMD with lower HF risk in black men
has, to our knowledge, not been previously reported. The
reason for this positive association in black men is unclear. It
is well established that blacks have a lower prevalence of low
BMD3,19 but a higher overall risk of HF18 compared with
whites. In our study, there were no black men who met the
criterion for osteoporosis at the total hip, with less than one
ﬁfth having osteopenia. Hence, any adverse relationship of
truly low BMD with HF risk may not have been observable in
this sample. In this context, the positive association of higher
BMDs could reﬂect their association with other HF risk
factors, such as increased adiposity, although the relationship
persisted after adjustment for body mass index and waist
circumference. An additional possibility is that black men in
our study had more vascular calciﬁcations in the ﬁeld of the
DXA scan, which could falsely elevate BMD while also
increasing HF risk. The original DXA scan images were not
available for review, however, and this possibility could not be
explored. Nevertheless, vascular calciﬁcation has been
reported to be less common in blacks than whites.37 Last,
the ﬁnding that the association did not hold up after
sensitivity analyses excluding participants with elevated
NT-proBNP or early HF events suggests that the association
in black men could have been biased by subclinical HF.
Regardless, the race interaction observed will require further
study in adequately powered samples.
Potential Explanations for Sex-Based Differences
In women, the basis for the lack of association of BMD and HF
risk is uncertain. It could relate to the fact that the prevalence
of osteoporosis in women is higher than in men and fostered
by the postmenopausal state.38 In this regard, the lack of
association could pertain to menopause being such a
dominant risk factor for osteoporosis that—given that all
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the women in our sample were postmenopausal—it could
overshadow other potentially weaker factors linking osteo-
porosis and incident HF. Indeed, sex hormones play an
important role in bone homeostasis and may affect cardiac
health, yet we were not able to assess the inﬂuence of
endogenous sex hormones in our study. Finally, although
stronger correlations of CVD risk factors with low BMD in
nonblack men could account for the observed sex differences,
there was no evidence that this was the case in our sample.
Study Limitations
There are a number of limitations to this study. BMD
measures were only available for a subset of the CHS cohort
attending the 1994–1995 visit obtained mainly at 2 sites.
The analysis included only 91 black men with 33 incident HF
events and 144 black women with 48 incident HF events.
There were no black men with osteoporosis and conse-
quently, given the race interaction found in men, our analysis
of BMD as a categorical variable included only nonblack
men. Also, the subset of CHS participants who survived and
attended the 1994–1995 visit to undergo DXA scanning was
healthier than the subset who did not.39 Hence, our ﬁndings
apply to healthier older adults and are not necessarily
generalizable to the broader older population. In addition, we
were not able to investigate the association of BMD with HF
with preserved ejection fraction versus HF with reduced
ejection fraction separately because of insufﬁcient sample
size. Nor were we able to explore the potential inﬂuence of
vitamin D, parathyroid hormone, FGF23, phosphate, or
calcium, which were only available in a small subset of the
study sample.
Potential Clinical Implications
Despite the previously described limitations, our study has
notable strengths, including use of DXA-based measures of
BMD, adjudicated HF end points, extensive adjustment for
potential confounders, and the ability to exclude subclinical
HF. Our ﬁndings therefore add to previous evidence linking
low BMD with higher incident HF risk speciﬁcally for (mostly)
white men, while calling into question a similar association for
(mostly) white women, but also suggest that shared pathways
may be at least partly involved in the pathogenesis of
osteoporosis and HF.
Conclusions
Our results provide impetus for additional research into the
molecular pathways linking osteoporosis and HF, which could
identify novel therapeutic targets for prevention of both
conditions. Moreover, these ﬁndings suggest that screening
for osteoporosis in whites may potentially offer opportunities
for earlier detection and prevention of HF, at least in men.
Further studies are needed to assess the sex- and race-based
differences documented here.
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Table S1. Cross-sectional Association of Continuous Femoral Neck BMD 
with Baseline Characteristics of Study Cohort 
Characteristics 
Femoral Neck BMD 









SD p value 
Age, years 734 -0.29  <0.001 516 -0.20  <0.001 
Body mass index, 
kg/m2 734 0.47  <0.001 516 0.31  <0.001 
Waist 
circumference, cm 731 0.41  <0.001 516 0.19  <0.001 
Systolic blood 
pressure, mmHg 734 0.02  0.632 516 0.02  0.661 
Anti-hypertensive 
medication           
    No 367  
0.63 ± 
0.12 <0.001 252  
0.79 ± 
0.14 0.749 
    Yes 367  
0.66 ± 
0.13  264  
0.78 ± 
0.15  
 Diabetes                                   
    No 646  
0.64 ± 
0.12 <0.001 426  
0.77 ± 
0.14 0.006 







    Yes 88  
0.72 ± 
0.14  90  
0.82 ± 
0.16  
Smoker                                  
    Never Smoker 367  
0.64 ± 
0.12 0.269 136  
0.78 ± 
0.15 0.732 
    Former Smoker 300  
0.66 ± 
0.13  339  
0.78 ± 
0.14  
    Current Smoker 67  
0.64 ± 
0.11  41  
0.79 ± 
0.13  
Alcohol, drinks/week 734 0.02  0.638 516 0.12  0.015 
Physical Activity 
(kcal/week)* 734 0.004  0.921 516 0.07  0.105 
Low-density 
lipoprotein (LDL), 
mg/dl 726 -0.01  0.769 509 0.02  0.642 
High-density 
lipoprotein (HDL), 
mg/dl 733 -0.03  0.494 516 0.01  0.836 
Triglycerides, mg/dl 734 0.07  0.062 516 0.05  0.238 
Lipid-lowering 
medication           
    No 651  
0.65 ± 
0.12 0.765 476  
0.78 ± 
0.15 0.587 







    Yes 83  
0.64 ± 
0.12  40  
0.77 ± 
0.16  
Aspirin                                        
    No 454  
0.65 ± 
0.12 0.465 302  
0.79 ± 
0.14 0.588 
    Yes 277  
0.64 ± 
0.12  212  
0.78 ± 
0.15  
Digitalis                                                    
    No 691  
0.65 ± 
0.12 0.838 469  
0.78 ± 
0.14 0.266 
    Yes 43  
0.65 ± 
0.15  47  
0.81 ± 
0.17  
Estrogen Use            
    None 597  
0.64 ± 
0.13 0.087      
    Yes 137  
0.66 ± 
0.12       
Prevalent coronary 
heart disease           
    No 623  
0.65 ± 
0.12 0.936 371  
0.78 ± 
0.14 0.624 
    Yes 111  
0.65 ± 
0.13  145  
0.78 ± 
0.15  









ischemic attack           
    No 707  
0.65 ± 
0.12 0.897 469  
0.79 ± 
0.14 0.194 
    Yes 27  
0.64 ± 




arterial disease           
    No 109  
0.65 ± 
0.14 0.896 95  
0.76 ± 
0.17 0.540 
    Yes 625  
0.65 ± 




fibrillation           
    No 696  
0.65 ± 
0.12 0.015 478  
0.78 ± 
0.15 0.475 
    Yes 38  
0.60 ± 
0.13  38  
0.80 ± 
0.14  
Creatinine, mg/dl 725 0.07  0.065 512 0.004  0.923 
Estimated 
glumerular filtration 
rate (eGFR, 734 0.05  0.143 516 0.07  0.112 










volume in 1 second, 
l 734 0.10  0.010 516 0.07  0.125 
C-reactive protein, 
mg/l 734 0.13  <0.001 516 0.05  0.272 
 
*The logarithm of physical activity + 1 was used to compute the correlation 
 
BMD: bone mineral density 
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